Abbvie Inc [ABBV] stock is trading at $189.29, down -0.22%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ABBV shares have gain 2.23% over the last week, with a monthly amount glided 15.53%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Abbvie Inc [NYSE: ABBV] stock has seen the most recent analyst activity on June 05, 2024, when HSBC Securities upgraded its rating to a Buy but kept the price target unchanged to $185 for it. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on May 17, 2024, and set its price target to $200. On January 29, 2024, upgrade upgraded it’s rating to Outperform. HSBC Securities downgraded its rating to a Hold. Goldman upgraded its rating to a Buy. Deutsche Bank started tracking with a Hold rating for this stock on November 09, 2023, and assigned it a price target of $150. In a note dated October 30, 2023, Barclays upgraded an Overweight rating on this stock and boosted its target price from $160 to $170.
Abbvie Inc [ABBV] stock has fluctuated between $135.85 and $190.97 over the past year. Currently, Wall Street analysts expect the stock to reach $166.81 within the next 12 months. Abbvie Inc [NYSE: ABBV] shares were valued at $189.29 at the most recent close of the market. An investor can expect a potential drop of -11.88% based on the average ABBV price forecast.
Analyzing the ABBV fundamentals
Abbvie Inc [NYSE:ABBV] reported sales of 55.00B for the trailing twelve months, which represents a growth of 4.31%. Gross Profit Margin for this corporation currently stands at 0.72% with Operating Profit Margin at 0.27%, Pretax Profit Margin comes in at 0.13%, and Net Profit Margin reading is 0.1%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.49 and Total Capital is 0.14. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of9.24.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 185.86 points at the first support level, and at 182.44 for the second support level. However, for the 1st resistance point, the stock is sitting at 193.31, and for the 2nd resistance point, it is at 197.34.
Ratios To Look Out For
For context, Abbvie Inc’s Current Ratio is 0.94. As well, the Quick Ratio is 0.83, while the Cash Ratio is 0.44. Considering the valuation of this stock, the price to sales ratio is 6.08, the price to book ratio is 41.74 and price to earnings (TTM) ratio is 63.19.
Transactions by insiders
Recent insider trading involved GONZALEZ RICHARD A, EXECUTIVE CHAIRMAN OF BOARD, that happened on Jul 17 ’24 when 0.28 million shares were sold. EVP, CHIEF BUS/STRAT OFFICER, Donoghoe Nicholas completed a deal on Mar 20 ’24 to sell 21082.0 shares. Meanwhile, EVP, CHIEF COMMERCIAL OFFICER Stewart Jeffrey Ryan sold 58949.0 shares on Mar 18 ’24.
